Abstract-Glucose is the main energy source of the body's cells and is essential for normal metabolism. Two pancreatic hormones, insulin and glucagon, are involved in glucose homeostasis. Alteration in the plasma glucose and insulin concentrations could lead to distinct symptoms and diseases, ranging from mental function impairment to coma and even death. Type 2 diabetes, insulin resistance and metabolic syndrome are typical examples of abnormal glucose metabolism that increase the risk for cardiovascular disease and mortality. The oral glucose tolerance test (OGTT) is a medical test used to screen for prediabetes, type 2 diabetes and insulin resistance. In the 5-sample 2-hour OGTT, plasma glucose and insulin concentrations are measured after a fast and then after oral intake of glucose, at intervals of 30 minutes. In this work, a statistical analysis is carried out to find significant differences between the five stages of the OGTT for plasma glucose and insulin data. In addition, the behavior of the glucose and insulin data is compared between subjects with the metabolic syndrome and marathon runners. Results show that marathon runners have plasma glucose and insulin levels significantly lower (p < 0.05) than people with the metabolic syndrome in all the stages of the OGTT. Insulin secretion decreases in marathon runners due to a significant reduction in plasma glucose concentration, but insulin secretion does not decrease in metabolic syndrome subjects due to insulin resistance, consequently plasma glucose concentration does not achieve normal levels.
I. INTRODUCTION
Glucose is the most abundant monosaccharide in the body and the major energy source of the body's cells. Glucose is essential for normal metabolism therefore plasma glucose concentration is regulated by a negative feedback mechanism by the pancreatic hormones insulin (secreted by the β-cells) and glucagon (secreted by the α-cells). A rise in plasma glucose concentration stimulates the secretion of insulin whereas a fall in plasma glucose concentration triggers the release of glucagon [1] .
Low plasma glucose concentration (hypoglycemia) impairs brain functions, alters the neuronal activity and may lead to hallucinations, nervousness, fainting, seizures, coma and even death [2] , [3] . In contrast, high plasma glucose concentration (hyperglycemia) can lead to cell dehydration, atherosclerosis (arterial thickening), stroke, kidney failure, nerve damage and blindness [4] , [5] . The deficiency of insulin secretion by pancreatic β-cells can lead to type 1 diabetes (insulin-dependent diabetes). On the other hand, high plasma insulin concentration (hyperinsulinemia) may lead to the development of hypoglycemia, type 2 diabetes and high blood pressure (hypertension), and increase the risk for cardiovascular disease [6] , [7] .
Impaired glucose tolerance and impaired fasting glucose are abnormal glucose metabolism associated with insulin resistance that increase the risk of developing type 2 diabetes and risk factors for cardiovascular disease and mortality [8] . Type 2 diabetes (a.k.a. noninsulin-dependent diabetes) is characterized by high plasma glucose concentration due to a defective hormonal control. In people with type 2 diabetes, hyperinsulinemia is the consequence of hyporesponsiveness of target tissues to the metabolic effects of insulin, a pathological condition called insulin resistance. Insulin resistance, abdominal obesity, fasting hyperglycemia, hypertension (high blood pressure), hypertriglyceridemia (increased blood triglycerides) and decreased blood highdensity lipoprotein-cholesterol are characteristic disorders of the metabolic syndrome. Several of these metabolic disorders of the syndrome increase the risk for cardiovascular disease and type 2 diabetes [9] , [10] . Unhealthy eating habits and physical inactivity predispose the development of metabolic syndrome and type 2 diabetes, so dietary modifications and exercise are important actions to prevent and treat diabetes and the metabolic syndrome [11] .
The oral glucose tolerance test (OGTT) measures the body's ability to process the glucose in the blood. The OGTT is the most common method to check glucose tolerance and is also used to screen for prediabetes, type 2 diabetes and gestational diabetes (diabetes during pregnancy). Data from the OGTT are also used to asses insulin resistance and insulin sensitivity [12] , [13] , [14] . The 5-sample 2-hour OGTT records the plasma glucose concentration after a fast and then records four blood samples more after oral intake of 75 grams of glucose, at intervals of 30 minutes. Besides, plasma insulin concentration at these time instants may also be measured. In all, ten different variables may be analyzed from the OGTT: five glucose levels and five insulin levels.
In a previous work we used these values of glucose and insulin to classify people using the K-means clustering algorithm [15] . We have shown that people with insulin resistance are grouped in a cluster when the HOMA-IR index is used as attribute to the clustering algorithm with two clusters. In addition, people with insulin resistance and marathon runners are grouped in different clusters when all values of glucose and insulin from the OGTT are used as attributes to the clustering algorithm with three clusters. These interesting results motivate us to analyze the plasma glucose and insulin data between the stages of the OGTT and between subjects. Specifically, we compare the glucose levels and the insulin levels at minutes 0, 30, 60, 90 and 120 of the OGTT, and we compare these glucose and insulin levels between subjects with the metabolic syndrome and marathon runners. The main goal of this work is to find clinical indicators that could serve to characterize and differentiate subjects with metabolic syndrome and marathon runners. A statistical analysis is carried out in this work to achieve the stated objectives.
II. METHODS

A. Glucose and insulin data
The 2-hour 75-gram OGTT was carried out on 30 male subjects at the University Hospital of Caracas, Venezuela. In the morning, after an overnight fast, subjects received 75 grams of glucose. Plasma glucose and insulin levels were measured from five blood samples, taken before (G 0 and I 0 at minute 0) and after (G 1 and I 1 at minute 30, G 2 and I 2 at minute 60, G 3 and I 3 at minute 90, and G 4 and I 4 at minute 120) the glucose intake.
Subjects were divided in two groups: 15 people (age = 31.40 ± 6.97 years) diagnosed with the metabolic syndrome according to the National Cholesterol Education Program-Adult Treatment Panel (NCEP ATP III) [16] and 15 professional marathon runners (age = 33 ± 8.21 years) with a weekly training of 180-240 km.
The study protocol adhered to the principles of the Declaration of Helsinki and was approved by the Ethical Committee of the University Hospital of Caracas; all the subjects gave a written informed consent.
B. Statistical analysis
For each group, mean and median values and standard deviations of the attributes (glucose and insulin) were computed. The Lilliefors test was used to quantify the normality of the glucose and insulin data, at a 5% significance level [17] . The Spearman's rank correlation coefficient (ρ) was calculated between pairs of glucose levels and between pairs of insulin levels. Significant correlations were also estimated.
The one-side (left and right) Wilcoxon rank-sum and Wilcoxon signed-rank hypothesis tests were used to assess significant differences in the median of the attributes. Specifically, the Wilcoxon signed-rank test was used to assess the differences of the attributes along the stages of OGTT since these are paired samples whereas the Wilcoxon rank-sum test was used to assess the differences between metabolic syndrome subjects and marathon runners since these are independent samples. A p-value less than 0.05 was considered statistically significant.
The statistical analysis was performed using Matlab's Statistics and Machine Learning Toolbox (Release 2015a). Table I shows mean values and standard deviations of the attributes for each group. The Lilliefors test rejects the null hypothesis at the 5% significance level that the data I 1 , I 2 , I 3 for subjects with the metabolic syndrome and I 0 for marathon runners come from a normal distribution. Tables II and III show the Spearman's rank correlation coefficient between pairs of glucose levels for people with metabolic syndrome and marathon runners, respectively. Tables IV and V show the Spearman's correlation coefficient between pairs of insulin levels for people with metabolic syndrome and marathon runners, respectively. Figure 1 shows the median values of the levels of glucose and insulin for each group during the 2-hour OGTT. We have found that people with the metabolic syndrome have median glucose levels G 1 (161) significantly greater (p < Metabolic syndrome patients have median insulin levels I 1 (70) significantly greater (p < 0.05) than I 0 (11), I 2 (70) significantly greater than I 0 , I 3 (75) significantly greater than I 0 , and I 4 (94) significantly greater than I 0 . However, marathon runners have median insulin levels I 1 (28.8) significantly greater than I 0 (2), I 2 (24), I 3 (21.4) and I 4 (16.6), I 2 significantly greater than I 0 and I 3 and I 4 , I 3 significantly greater than I 0 and I 4 , and I 4 significantly greater than I 0 .
III. RESULTS
A. Descriptive statistics
B. Glucose and insulin levels comparison between the stages of the OGTT
C. Glucose and insulin levels comparison between groups
Compared to marathon runners, people with the metabolic syndrome have significantly greater median glucose levels 
IV. DISCUSSION
The result of the Lilliefors test indicates that insulin data (except I 4 ) for metabolic syndrome subjects do not follows a normal distribution. In contrast, the failure to reject the null hypothesis that the glucose samples are normally distributed may reflect normality in the population or it may reflect a lack of strong evidence against the null hypothesis due to the small sample size. Besides, I 1 , I 2 , I 3 and I 4 may follow a normal distribution in marathon runners.
Significant correlations obtained using the Spearman's ρ suggest the dependence of the glucose and insulin data along the stages of the OGTT. Indeed, these data could Excluding the lack of correlation (as expected) between plasma glucose concentration at fast and 30 minutes after the glucose intake, we have observed that consecutive plasma glucose concentrations after the glucose intake are significant correlated in marathon runners (30 and 60 min, 60 and 90 min, and 90 and 120 min). For subjects with metabolic syndrome, consecutive plasma glucose concentration measurements 30 minutes after the glucose intake was significant correlated with that at 60 minutes, and 60 minutes with 90 minutes, but plasma glucose concentration at minute 120 was not significant correlated (ρ = 0.249) with the previous sample (minute 90). This could be a result of the metabolic disorder presented in this population.
Significant correlations observed in consecutive plasma insulin measurements in marathon runners (except between I 0 and I 1 ) show that plasma insulin concentration depends on the previous sample, a typical time series behavior. Moreover, the significant correlations found in all measurements of plasma insulin (even between I 0 and I 1 ) in metabolic syndrome subjects could be a result of the non-normality distributions of the insulin data (as quantified with the Lilliefors test). The same explanation applies for I 0 in marathon runners, significant correlated with I 2 , I 3 and I 4 .
We have observed that people with the metabolic syndrome have plasma glucose and insulin levels significantly greater than marathon runners in all the stages of the OGTT. In marathon runners, a significant plasma glucose concentration increases was observed 30 minutes after the oral intake of glucose followed by a significant plasma glucose concentration decreases in the following OGTT stages (G 2 < G 1 , G 3 < G 2 and G 4 < G 3 ). This plasma glucose concentration behavior was not observed in metabolic syndrome subjects where glucose levels significant increase from 0 to 30 minutes (G 0 < G 1 ) and then significant decrease from 60 to 90 minutes (G 3 < G 2 ) and from 90 to 120 minutes (G 4 < G 3 ), but an increase (not significant) in the glucose levels was observed from 30 to 60 minutes (G 1 < G 2 ). Also, plasma glucose concentration at fast in marathon runners is only significantly lower than that at 30 minutes after the glucose intake, but plasma glucose concentration at fast in metabolic syndrome subjects is significantly lower than the rest of the OGTT stages (minutes 30-120). This means that the hormone insulin in marathon runners can effectively process the excess of blood glucose, but the metabolic disorders in metabolic syndrome subjects avoid the removal of excess blood glucose.
In marathon runners, insulin is released from the pancreas by a negative feedback mechanism to maintain normal glucose homeostasis. Plasma insulin concentration significant increases 30 minutes after the glucose intake and then significant decreases in the following OGTT stages (I 2 < I 1 , I 3 < I 2 and I 4 < I 3 ). But in subjects with metabolic syndrome, plasma insulin concentration increases significantly 30 minutes after the glucose intake and increases but not significantly for the next OGTT stages and, by the end of the OGTT, insulin concentration has not decrease; insluin levels mean values show a peak at 1 h (I 2 ) as shown in Table I . These results are in agreement with previous works and highlight the condition of insulin resistance in metabolic syndrome subjects [9] , [11] , [18] .
V. CONCLUSIONS
The OGTT allowed us to observe the negative feedback action of the hormone insulin to reduce plasma glucose concentration. This control action was observed in marathon runners but not in people with the metabolic syndrome. In marathon runners, as plasma glucose concentration increase significantly as a result of glucose intake, insulin is released by the pancreas to lower plasma glucose concentration, then insulin secretion decreases significantly (p < 0.05) due to a significant reduction (p < 0.05) in plasma glucose concentration. In contrast, in people with metabolic syndrome, insulin is released by the pancreas as plasma glucose concentration increase as a result of glucose intake, but plasma glucose concentration does not achieve normal levels due to the insulin resistance condition in these subjects.
Moreover, we have shown that marathon runners have plasma glucose and insulin levels significantly lower than people with the metabolic syndrome in all the stages of the OGTT. This could be a result of the intensive exercise training and healthy eating habits in marathon runners, in contrast with people with metabolic syndrome characterized by a sedentary lifestyle, unhealthy eating habits and metabolic disorders.
